Investing.com -- 10X Genomics Inc (NASDAQ:TXG) shares rose 3.8% Wednesday following the announcement of a research collaboration with Cleveland Clinic focused on bladder cancer biomarker discovery.
The multi-year partnership aims to identify biomarkers that may predict patient response to antibody-drug conjugate treatments using 10X Genomics’ single cell and spatial analysis platforms, including Flex Apex, Xenium, and the recently announced Atera platform.
The collaboration will examine tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens. Researchers plan to analyze tumor microenvironment composition, immune cell infiltration, and expression of therapeutic targets to better understand mechanisms of response and resistance to therapies such as antibody-drug conjugates and immunotherapies.
"We look forward to collaborating with 10x Genomics on this promising work. This collaboration has the potential to shed new light into the mechanisms underlying therapeutic response in a number of major cancer types," commented Timothy Chan, MD, PhD, Chair, Department of Cancer Sciences at Cleveland Clinic.
The study is expected to integrate single-cell transcriptomic profiling, spatial gene expression, and protein measurements to generate a comprehensive dataset linking single cell and spatial insights with clinical outcomes.
10X Genomics stated the collaboration is part of its broader efforts to partner with research institutions to generate evidence needed to support future development of diagnostic applications across oncology and other disease areas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what TXG is really worth.Get instant clarity on TXG—plus thousands of other stocks—before the opportunity disappears.